Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis
核心洞察
Calluna Pharma (搜索) completed enrollment in its Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis (搜索), enrolling 161 patients more than six months ahead of schedule.
CAL101 is a first-in-class monoclonal antibody targeting S100A4 (搜索), a novel upstream pathway implicated in fibrotic disease (搜索) progression.
The randomized, double-blind, placebo-controlled trial will evaluate CAL101's efficacy and safety with topline data expected in Q1 2027.
Calluna Pharma (搜索) AS, a clinical-stage biotechnology company, has completed enrollment in its global Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis (搜索) (IPF (搜索)), finishing more than six months ahead of schedule. The randomized, double-blind, placebo-controlled trial enrolled 161 adult patients with IPF across more than 50 sites in the US, UK, EU, Turkey, and South Korea.
Novel Therapeutic Approach Targets Upstream Fibrotic Pathway
CAL101 represents a first-in-class monoclonal antibody targeting S100A4 (搜索), a DAMP (damage-associated molecular pattern) protein that serves as a novel upstream pathway implicated in fibrotic disease (搜索). When tissue is stressed or injured, S100A4 becomes activated, triggering multiple downstream pathways associated with pathological activation and proliferation of fibroblasts—the key effector cells driving progression of fibrosis.
The therapeutic approach aims to re-establish tissue homeostasis by switching off the downstream pathways involved in the persistent and maladaptive scar tissue formation characteristic of IPF (搜索). This upstream targeting strategy represents a departure from current treatment approaches and offers potential applicability across diverse fibrotic conditions.
Study Design and Timeline
The AURORA study follows a rigorous design with patients undergoing an initial 28-day screening period before randomization to receive monthly intravenous infusions of CAL101 or placebo for six months at a 3:2 randomization ratio. The study's primary endpoint focuses on lung function preservation, measured by change from baseline in forced vital capacity (FVC).
"The completion of enrollment in AURORA is an important operational milestone for Calluna," said Jonas Hallén, M.D., Ph.D., Co-Founder and Chief Medical Officer of Calluna Pharma (搜索). "We are deeply grateful to the patients who chose to participate in this study, and to the investigators and site teams whose commitment and efficiency enabled rapid enrollment across a broad range of countries and sites."
Calluna anticipates topline data from the AURORA study in Q1 2027, which will provide comprehensive understanding of CAL101's safety profile and potential efficacy in IPF (搜索) patients.
Preclinical and Early Clinical Evidence
A randomized, double-blind, placebo-controlled Phase 1 study of CAL101 demonstrated a favorable safety profile, predictable pharmacokinetic properties, and pharmacodynamic effects consistent with extracellular S100A4 (搜索) neutralization. Preclinical studies have shown CAL101's ability to prevent and treat fibrosis while modifying the disease-specific activation of fibroblasts.
Addressing Significant Unmet Medical Need
Idiopathic pulmonary fibrosis (搜索) represents a progressive lung disease where an inappropriately activated wound-healing response causes lung tissue to become thickened and scarred, making breathing increasingly difficult. The disease primarily affects older adults and impacts approximately 233,000 people in the US and EU.
The exact triggers of IPF (搜索) remain unknown, though the condition is believed to result from a combination of genetic and environmental factors. Over time, lung scarring worsens, leading to respiratory failure and ultimately death, with a median survival rate of 3-5 years.
"We are thrilled with the rapid and high-quality execution of the AURORA study," said Mark Gaffney, Chief Executive Officer and Board member of Calluna Pharma (搜索). "AURORA enables us to have a comprehensive understanding of CAL101 and its readiness for late-stage and pivotal studies in pulmonary fibrosis as well as its potential in other inflammatory or fibrotic diseases."